Data Supplement

• Supplemental Data -

  Supplemental Figure 1. Effect of RS-ketamine on phosphorylation of ERK1/2 in CHO-MOR cells.
  

  Supplemental Figure 2. RS-ketamine modulates MOR-mediated signaling.
  

  Supplemental Figure 3. Effects of RS-ketamine on opioid peptide-mediated G-protein activity at MOR, DOR, and KOR.
  

  Supplemental Figure 4. Effects of ketamine enantiomers (R-ketamine and S-ketamine) on Gprotein activity and

  β-arrestin recruitment mediated by Met-enkephalin at MOR.

  Supplemental Figure 5. Effects of ketamine metabolites on G-protein activity and β-arrestin recruitment mediated by Met-enkephalin at MOR.
  

  Supplemental Table 1. Analysis of phosphoERK1/2 levels at MOR in the presence of RS-ketamine.
  

  Supplemental Table 2. Analysis of effect of RS-ketamine on DAMGO-, Met-enkephalin- or morphine-mediated signaling at MOR.
  

  Supplemental Table 3. Analysis of effect of RS-ketamine on Leu-enkephalin- or Dynorphin A17-mediated [³⁵S]GTPyS
  binding at MOR.
  

  Supplemental Table 4. Analysis of effect of RS-ketamine on Met-enkephalin-, Leu-enkephalin-, or Dynorphin A17-mediated [³⁵S]GTPyS binding at DOR.
  

  Supplemental Table 5. Analysis of effect of RS-ketamine on Met-enkephalin-, Leu-enkephalin-, or Dynorphin A17-mediated [³⁵S]GTPyS binding at KOR.
  

  Supplemental Table 6. Analysis of effect of R- and S-ketamine on Met-enkephalin-mediated signaling at MOR.
  

  Supplemental Table 7. Analysis of effect ketamine metabolites on Met-enkephalin-mediated signaling at MOR.
  

  Supplemental Table 8. Description of statistical analysis for different figures.